Does the urinary tract infection caused by carbapenem-resistant Gram-negative bacilli impact the outcome of kidney transplant recipients?

Carregando...
Imagem de Miniatura
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2018
Editora
WILEY
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
TRANSPLANT INFECTIOUS DISEASE, v.20, n.4, article ID e12923, 11p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The incidence of urinary tract infection (UTI) after kidney transplantation (KT) caused by multidrug-resistant (MDR) bacteria is growing. The aim of this study was to analyze the impact of UTI caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) in the survival of graft and recipients following KT. This was a retrospective cohort study involving patients who underwent KT between 2013 and 2016. Patients were followed since the day of the KT until loss of graft, death or end of the follow-up period (31th December 2016). The outcomes measured were UTI by MDR following KT and graft and patient survival. Analyses were performed using Cox regression; for the graft and patient survival analysis, we used a propensity score for UTI by CR-GNB to matching a control group. UTI was diagnosed in 178 (23.9%) of 781 patients, who developed 352 UTI episodes. 44.6% of the UTI cases were caused by MDR bacteria. Identified risk factors for UTI by MDR bacteria were DM, urologic disease as the cause of end-stage renal failure, insertion of ureteral stent, carbapenem use, and delayed graft function (DGF). Risk factors for death during the follow-up period were female gender, patients over 60years old at the time of KT, DM, body mass index over 31.8, UTI caused by CR-GNB. In conclusion, UTIs caused by CR-GNB have great impact on patients' survival after KT.
Palavras-chave
carbapenem resistance, diabetes mellitus, kidney transplantation, Klebsiella pneumoniae, mortality, multidrug resistance, Pseudomonas aeruginosa, risk factor, urinary tract infection
Referências
  1. Alci E, 2015, TRANSPL P, V47, P1433, DOI 10.1016/j.transproceed.2015.04.064
  2. Ariza-Heredia EJ, 2013, ANN TRANSPL, V18, P195, DOI 10.12659/AOT.883901
  3. Bodro M, 2015, AM J TRANSPLANT, V15, P1021, DOI 10.1111/ajt.13075
  4. Bodro M, 2013, TRANSPLANTATION, V96, P843, DOI 10.1097/TP.0b013e3182a049fd
  5. Chacon-Mora N, 2017, ENFERM INFEC MICR CL, V35, P255, DOI 10.1016/j.eimc.2016.03.003
  6. Chapman TM, 2003, DRUGS, V63, P2803, DOI 10.2165/00003495-200363240-00009
  7. Cicora F, 2013, TRANSPL P, V45, P3389, DOI 10.1016/j.transproceed.2013.07.064
  8. Cockerill FR, 2015, M100S25 CLIN LAB STA, V35, P44
  9. Espinar MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134737
  10. Fiorante S, 2010, KIDNEY INT, V78, P774, DOI 10.1038/ki.2010.286
  11. Freire MP, 2015, INFECTION, V43, P315, DOI 10.1007/s15010-015-0743-4
  12. Freire MP, 2015, TRANSPLANTATION, V99, P521, DOI 10.1097/TP.0000000000000381
  13. Freire MP, 2017, TRANSPLANTATION, V101, P811, DOI 10.1097/TP.0000000000001620
  14. Freire MP, 2016, J ANTIMICROB CHEMOTH, V71, P2577, DOI 10.1093/jac/dkw165
  15. Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI 10.1093/cid/ciq257
  16. Gutierrez-Gutierrez B, 2017, LANCET INFECT DIS, V3099, P1
  17. Huprikar S, 2016, AM J TRANSPLANT, V16, P403
  18. Lee JR, 2013, TRANSPLANTATION, V96, P732, DOI 10.1097/TP.0b013e3182a04997
  19. Lim JH, 2013, TRANSPL P, V45, P1584, DOI 10.1016/j.transproceed.2012.12.011
  20. Liu Y, 2010, TRANSPL P, V42, P1667, DOI 10.1016/j.transproceed.2010.02.088
  21. Ljungman P, 2017, CLIN INFECT DIS, V64, P87, DOI 10.1093/cid/ciw668
  22. Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107
  23. Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x
  24. Mitra Subhashis, 2011, Curr Infect Dis Rep, V13, P579, DOI 10.1007/s11908-011-0210-z
  25. Origuen J, 2016, TRANSPL INFECT DIS, V18, P575, DOI 10.1111/tid.12547
  26. Parasuraman R, 2013, AM J TRANSPLANT, V13, P327, DOI 10.1111/ajt.12124
  27. Pouch SM, 2015, TRANSPL INFECT DIS, V17, P800, DOI 10.1111/tid.12450
  28. Pouch SM, 2016, VIRULENCE, V5594, P1
  29. Satlin MJ, 2014, CLIN INFECT DIS, V58, P1274, DOI 10.1093/cid/ciu052
  30. Siedlecki A, 2011, AM J TRANSPLANT, V11, P2279, DOI 10.1111/j.1600-6143.2011.03754.x
  31. Simkins J, 2014, TRANSPL INFECT DIS, V16, P775, DOI 10.1111/tid.12276
  32. Singh R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1432-3
  33. Singh R, 2015, CURR OPIN INFECT DIS, V28, P112, DOI 10.1097/QCO.0000000000000120
  34. Tawab KA, 2017, EXP CLIN TRANSPLANT, V15, P157, DOI 10.6002/ect.2016.0069
  35. vansLoon K, 2017, ANTIMICROB AGENTS CH, V62
  36. Vidal E, 2012, TRANSPL INFECT DIS, V14, P595, DOI 10.1111/j.1399-3062.2012.00744.x
  37. Vidal E, 2015, ENFERM INFEC MICR CL, V33, P679, DOI 10.1016/j.eimc.2015.03.024
  38. Wu XH, 2016, AM J INFECT CONTROL, V44, P1261, DOI 10.1016/j.ajic.2016.04.222